Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials
Tetraphase Pharmaceuticals (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, announced data from two post-hoc analyses of pooled data from two Phase 3 IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) studies of XERAVA in patients with complicated intra-abdominal infections (cIAI). As quoted in the press release: These data were presented at …
Tetraphase Pharmaceuticals (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, announced data from two post-hoc analyses of pooled data from two Phase 3 IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) studies of XERAVA in patients with complicated intra-abdominal infections (cIAI).
As quoted in the press release:
These data were presented at the 2018 American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy, held October 20-23 in Seattle, WA.
“Treatment failure risk can increase in certain subgroups with cIAI, including patients who are obese, and those with altered renal function,” said Larry Tsai, M.D., Chief Medical Officer of Tetraphase. “Obesity may put patients at higher risk due to altered pharmacokinetics and comorbidities, while renal function can be highly dynamic in patients with serious infections, which can result in significant over- or under-dosing of antibiotics.”
Dr. Tsai added, “We believe the data presented at the 2018 ACCP Global Conference confirm the efficacy of XERAVA in both obese and renally impaired high-risk patient populations. In fact, one of the many benefits of XERAVA is that physicians do not have to dose adjust the therapy for renally impaired patients, which when combined with this post-hoc sub-analysis, highlight how XERAVA is an ideal option for those with altered renal function. Overall, these pooled data from two Phase 3 IGNITE studies further reinforce the use of XERAVA as an empiric treatment of choice for appropriate patients.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1790.96 | -3.02 | |
Silver | 20.46 | -0.05 | |
Copper | 3.60 | +0.01 | |
Palladium | 2204.00 | -9.00 | |
Platinum | 938.00 | +3.00 | |
Oil | 89.31 | -1.19 | |
Heating Oil | 3.28 | -0.06 | |
Natural Gas | 7.84 | 0.00 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured {{ post.primary_section_name }} Stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â